Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Erasca, Inc. (ERAS : NSDQ)

• Company Description    Erasca Inc. is a clinical-stage precision oncology company singularly focused on discovering, developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Erasca Inc. is based in SAN DIEGO. Number of Employees: 103

• Price / Volume Information    Yesterday's Closing Price: $10.27 Daily Weekly Monthly 20 Day Moving Average: 9,547,542 shares Shares Outstanding: 310.98 (millions) Market Capitalization: $3,193.81 (millions) Beta: 0.68 52 Week High: $24.28 52 Week Low: $1.06 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -52.69% -54.57% 12 Week -21.12% -27.15% Year To Date 176.07% 155.28%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3115 MERRYFIELD ROW SUITE 300 - SAN DIEGO,CA 92121 USA ph: 858-465-6511 fax: - ir@erasca.com http://www.erasca.com

• General Corporate Information    Officers Jonathan E. Lim - Chief Executive Officer; Chairman and Co-Founder David M. Chacko - Chief Financial Officer and Chief Business Officer Michael D. Varney - Chair of Research and Development and Director James A. Bristol - Director Alexander W. Casdin - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 29479A108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 310.98 Most Recent Split Date: (:1) Beta: 0.68 Market Capitalization: $3,193.81 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.12 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.55 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 13.28% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 8.12 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: -10.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -35.31 12/31/25 - -34.48 09/30/25 - -33.10 ROA 03/31/26 - -29.49 12/31/25 - -28.74 09/30/25 - -27.76 Current Ratio 03/31/26 - 9.52 12/31/25 - 10.04 09/30/25 - 10.45 Quick Ratio 03/31/26 - 9.52 12/31/25 - 10.04 09/30/25 - 10.45 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 1.27 12/31/25 - 1.05 09/30/25 - 1.23 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©